1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. Financials
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
321.23 USD   +1.62%
05/20DEXCOM INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/17Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating
MT
05/11TRANSCRIPT : DexCom, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 02:40 PM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 20 02135 50352 04231 521--
Enterprise Value (EV)1 20 63436 35352 69231 45731 41931 058
P/E ratio 199x73,1x346x86,4x73,3x54,6x
Yield ------
Capitalization / Revenue 13,6x18,4x21,3x10,8x9,01x7,53x
EV / Revenue 14,0x18,9x21,5x10,8x8,98x7,42x
EV / EBITDA 98,3x94,1x111x44,3x34,3x25,5x
Price to Book 22,7x21,1x23,1x11,8x10,0x8,89x
Nbr of stocks (in thousands) 91 52996 02896 92298 126--
Reference price (USD) 219370537321321321
Announcement Date 02/13/202002/11/202102/10/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 1 4761 9272 4492 9173 5004 184
EBITDA1 2103874737109161 216
Operating profit (EBIT)1 161319371462640848
Operating Margin 10,9%16,6%15,1%15,8%18,3%20,3%
Pre-Tax Profit (EBT)1 104225174404584795
Net income1 101494155380452612
Net margin 6,85%25,6%6,32%13,0%12,9%14,6%
EPS2 1,105,061,553,724,385,89
Dividend per Share2 ------
Announcement Date 02/13/202002/11/202102/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 650698629695762828
EBITDA1 149131112176199217
Operating profit (EBIT)1 12499,050,3107140165
Operating Margin 19,0%14,2%8,00%15,5%18,4%19,9%
Pre-Tax Profit (EBT)1 90,7-14,736,197,7130156
Net income1 70,9-19,497,376,397,6117
Net margin 10,9%-2,78%15,5%11,0%12,8%14,1%
EPS2 0,71-0,200,930,730,931,19
Dividend per Share ------
Announcement Date 10/28/202102/10/202204/28/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 614850650---
Net Cash position1 ---63,8102463
Leverage (Debt / EBITDA) 2,92x2,20x1,38x-0,09x-0,11x-0,38x
Free Cash Flow1 13527753,3184402667
ROE (Net Profit / Equities) 22,0%22,3%13,1%13,9%16,8%19,1%
Shareholders' equity1 4592 2101 1832 7332 6953 205
ROA (Net Profit / Asset) 4,69%9,05%5,83%5,81%9,28%12,4%
Assets1 2 1565 4542 6556 5444 8754 950
Book Value Per Share2 9,6417,523,227,332,036,1
Cash Flow per Share2 3,414,884,424,796,687,65
Capex1 180199389333297317
Capex / Sales 12,2%10,3%15,9%11,4%8,48%7,58%
Announcement Date 02/13/202002/11/202102/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 31 520 993 457
Net sales (USD) 2 448 500 000
Number of employees 6 300
Sales / Employee (USD) 388 651
Free-Float 99,5%
Free-Float capitalization (USD) 31 360 399 171
Avg. Exchange 20 sessions (USD) 313 473 066
Average Daily Capital Traded 0,99%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA